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Abstract
HIV-1 establishes infection in astrocytes and macroage-lineage cells of the central nervous system (CNS). Certain
antiretroviral drugs (ARVs) can penetrate the CNS, and are therefore often used in neurologically active combined
antiretroviral therapy (Neuro-cART) regimens, but their relative activity in the different susceptible CNS cell populations is
unknown. Here, we determined the HIV-1 inhibitory activity of CNS-penetrating ARVs in astrocytes and macrophage-lineage
cells. Primary human fetal astrocytes (PFA) and the SVG human astrocyte cell line were used as in vitro models for astrocyte
infection, and monocyte-derived macrophages (MDM) were used as an in vitro model for infection of macrophage-lineage
cells. The CNS-penetrating ARVs tested were the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC),
lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), etravirine (ETR) and nevirapine
(NVP), and the integrase inhibitor raltegravir (RAL). Drug inhibition assays were performed using single-round HIV-1 entry
assays with luciferase viruses pseudotyped with HIV-1 YU-2 envelope or vesicular stomatitis virus G protein (VSV-G). All the
ARVs tested could effectively inhibit HIV-1 infection in macrophages, with EC90s below concentrations known to be
achievable in the cerebral spinal fluid (CSF). Most of the ARVs had similar potency in astrocytes, however the NRTIs 3TC, d4T
and ZDV had insufficient HIV-1 inhibitory activity in astrocytes, with EC90s 12-, 187- and 110-fold greater than achievable CSF
concentrations, respectively. Our data suggest that 3TC, d4T and ZDV may not adequately target astrocyte infection in vivo,
which has potential implications for their inclusion in Neuro-cART regimens.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) penetrates the
central nervous system (CNS) during acute infection or sometime
shortly thereafter. Later in the course of HIV-1 disease it
frequently causes encephalitis (HIVE), HIV-associated dementia
(HAD) or less severe HIV-associated neurocognitive disorders
(HAND) [1]. While it is the macrophage-lineage cells of the CNS
that support productive HIV-1 replication, specifically the
perivascular macrophages and microglia [1,2], astrocytes undergo
a restricted infection [3–5]. Nonetheless, recent studies have
demonstrated that up to 19% of astrocytes can become infected in
patients with the most severe HAD and HIVE, and therefore
astrocytes potentially represent a significant viral reservoir [6].
Furthermore, whilst astrocyte infection is restricted, their infection
results in cellular dysfunction. This is associated with changes in
gene expression [7], loss of neuronal support, reduced ability to
maintain glutamate levels and loss of integrity of the blood-brain
barrier (BBB) [1,4], likely contributing to the development of
HAND.
Certain antiretroviral drugs (ARVs) have been shown to have
potentially superior CNS efficacy, as determined by the CNS
penetration-effectiveness (CPE) scoring system, which is based on
available drug concentrations in the cerebrospinal fluid (CSF) [8,9]
and clinical data showing improved neurocognitive outcomes.
These ARVs include the nucleoside reverse transcriptase inhibitors
(NRTIs) abacavir (ABC), emtricitabine (FTC), lamivudine (3TC),
stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz
(EFV), delavirdine (DLV), etravirine (ETR) and nevirapine (NVP),
the protease inhibitors (PIs) indinavir (IDV), darunavir (DRV),
lopinavir (LPV), the CCR5 antagonist maraviroc (MVC), and the
integrase inhibitor raltegravir (RAL). Because of their favorable
CNS penetration, these agents are used in so-called ‘‘neurologi-
cally active combined antiretroviral therapy’’, or Neuro-cART
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regimens, with the premise that their superior bioavailability in the
CNS would be optimal for treating CNS infection [10,11].
However, the relative activity of CNS-penetrating ARVs in the
different susceptible CNS cell types has yet to be determined.
Furthermore, whether any or all of these agents have HIV-1
inhibitory activity in astrocytes at physiologically relevant concen-
trations is unknown.
In this study, we determined the HIV-1 inhibitory activity of the
NRTIs ABC, 3TC, d4T and ZDV, the non-NRTIs EFV, ETR
and NVP, and the integrase inhibitor RAL in cellular models of
brain macrophage-lineage cells and astrocytes, with comparison to
peripheral blood mononuclear cells (PBMC). Our results show
that whilst all the ARVs tested have potent inhibitory activity in
macrophages and PBMC at physiologically relevant concentra-
tions, the NRTIs 3TC, d4T and ZDV have inadequate inhibitory
activity in astrocytes, with 90% inhibitory concentrations (EC90)
exceeding those achievable in the CSF. These results suggest that
3TC, d4T and ZDV may not effectively target astrocyte infection




The characteristics of the ARVs used in the study are
summarized in Table 1 and all were prepared as 10 mM stocks
in DMSO except for RAL, which was prepared in water. The
ARVs were chosen to predominantly represent those used in
current Neuro-cART regimens [12], and consisted of NRTIs,
NNRTIs and integrase inhibitors. While protease inhibitors are
currently used in Neuro-cART, we were unable to analyze them in
this study because of the single round virus assay used here and the
nature of our luciferase readout.
Human ethics approval
Human fetal brain tissue and PBMC were obtained following
informed written consent from all participants in the study. This
has been respectively approved by the Human Ethics Committees
from St Vincent’s Hospital (HREC 08284) and from the
University of New South Wales (UNSW Ethic approval HREC
03187).
Cell lines and primary cells
The SVG astrocyte cell line [13] was cultured in Minimum
Essential Medium (MEM) supplemented with 20% (vol/vol) heat-
inactivated fetal calf serum (HI-FCS), 100 mg/ml of penicillin and
streptomycin, and 2 mM of GlutaMAX (Invitrogen, USA).
Primary human fetal astrocytes (PFA) were prepared as previously
described [14], and were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% (vol/vol) HI-FCS,
100 mg/ml of penicillin and streptomycin, and 2 mM of
GlutaMAX (Invitrogen). PBMC were purified from the blood of
healthy HIV-1-negative donors, stimulated with 5 mg/ml of
phytohemagglutinin (Sigma, USA) for 3 days, and cultured in
RPMI 1640 medium supplemented with 10% (vol/vol) HI-FCS,
100 mg/ml of penicillin and streptomycin, and 20 U/ml of
interleukin-2 (Roche, Switzerland). Monocyte-derived macrophag-
es (MDM) were produced from elutriated monocytes that were
cultured for 5 days in RPMI 1640 medium supplemented with
10% (vol/vol) pooled human sera, 100 mg/ml of penicillin and
streptomycin, and 12.5 ng/ml of macrophage colony-stimulating
factor (M-CSF).
Production and quantitation of Env-pseudotyped
luciferase reporter viruses
Env-pseudotyped luciferase reporter viruses were produced by
transfection of 293T cells with pCMVDP1DenvpA, pHIV-1Luc,
and either pcDNA3-VSVg or pSVIII-YU2 Env plasmids using
Lipofectamine 2000 (Invitrogen) at a ratio of 1:3:1, as described
previously [15–17]. Viruses pseudotyped with the CCR5-using
HIV-1 YU-2 envelope glycoproteins were used for infections of
PBMC and MDM, whereas SVG cells and PFA were infected with
viruses pseudotyped with the vesicular stomatitis virus G protein
(VSV-G) in order to achieve sufficient levels of viral entry for the
inhibition assays. The supernatants containing virus pseudotypes
Table 1. Biological and pharmacological properties of the ARVs.
ARV Abbreviation ARV Classa Neuro-cART ARV concentrations (mM)
Highest non-toxic
concentration of ARV (mM)f
Plasmab CSFc IC50
d CPEe
Abacavir ABC NRTI Yes 5.2–10.9 0.5–1.8 0.2–1.5 3 45
Lamivudine 3TC NRTI Yes 4.4–8.7 0.05–1.1 0.8–4.9 2 60
Stavudine d4T NRTI Yes 3.4–6.4 0.2–0.4 0.3–2.1 2 50
Zidovudine ZDV NRTI Yes 4.5–6.7 0.1–0.4 0.01–0.04 4 50
Efavirenz EFV NNRTI Yes 9.2–16.6 0.01–0.09 0.01–0.05 3 0.3
Etravirine ETR NNRTI Yes 0.2–0.4 0.01–0.02 0.001–0.2 2 1
Nevirapine NVP NNRTI Yes 7.5–16.9 1.3–10.9 0.02–0.1 4 10
Raltegravir RAL INI Yes 0.1–4.5 0.01–0.3 0.002–0.01 3 1
aNRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside reverse transcriptase inhibitor; INI, Integrase inhibitor.
bThe in vivo plasma concentration range [36].
cThe in vivo cerebrospinal fluid (CSF) concentration range [36].
d50% inhibitory concentration range for HIV-1 [36].
eCPE, CNS penetration-effectiveness (The scale is from 1 to 4, with 4 being the most favorable CNS penetration-effectiveness) [12].
fHighest non-cytotoxic concentrations evaluated in a cell culture system in all cell types (SVG, PFA, PBMC, and MDM cells).
doi:10.1371/journal.pone.0062196.t001
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were harvested 48 h later, filtered through 0.45 mm filters, titrated
on each of the different cell types (TCID50 values were calculated),
and stored at 280uC.
Cell viability assay
ARV cytotoxicity was assessed in all cell types at 72 h post-drug
exposure using the CellTitre-Glo Luminescent Cell Viability Assay
(Promega, USA), according to the manufacturer’s protocol.
Virus inhibition assays
Assays were performed in all cell types in the presence of
titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000
PBMC, or 50,000 MDM cells/well were seeded into triplicate
wells of 96-well plates. Twenty-four hours later, the culture
medium was removed and replaced with medium containing the
ARV or DMSO (0.5% vol/vol), and equivalent TCID50 infectious
units of luciferase reporter virus were added to the cells. After a
16 h incubation at 37uC, the initial viral inoculum was removed
and replaced with culture medium containing the same ARV or
DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the
medium was aspirated, the cells were lysed and HIV-1 infection
measured using the Luciferase Assay System (Promega) according
to manufacturer’s instructions. Luminescence was measured using
a FLUOStar Optima microplate reader (BMG Labtech, Ger-
many). Inhibition curves and the 50% (EC50) and 90% (EC90)
effective concentrations were determined by nonlinear regression
analysis as previously described [16–18], using GraphPad Prism
software (version 5.0d; GraphPad Software, USA).
Results
Inhibitory activity of CNS-penetrating ARVs in CNS cell
models
We first evaluated the cellular cytotoxicity of the ARVs in the
cell types studied. The characteristics of the ARVs, including their
achievable plasma and CSF concentrations, inhibitory concentra-
tion ranges, CPE scores, and whether they have been used in
Neuro-cART regimens are summarized in Table 1. None of the
ARVs showed evidence of cytotoxicity at the highest concentra-
tions tested in the virus inhibition assays (Table 1). Mitochondrial
toxicity of the ARVs was not tested. Next, we evaluated the
inhibitory activity of all the CNS-penetrating ARVs in cell models
that represent brain astrocytes (the SVG astrocyte cell line and
PFA), and brain macrophage-lineage cells (MDM), with compar-
ison to that in a cell model that represents activity in the peripheral
blood (PBMC). MDM were chosen as a model for brain
macrophage-lineage cells because cell lines for perivascular
macrophages do not exist and those for microglia are particularly
poor at representing in vivo microglia. In addition, primary cells are
extremely hard to obtain and difficult to culture and use. Our
previous studies have shown that the HIV-1 replication charac-
teristics in MDM recapitulate those observed in primary cultures
of human fetal microglia [19], confirming their suitability as a
convenient in vitro cellular model for macrophage-lineage cells in
vivo. Virus inhibition curves are shown in Figure 1, and the EC50
and EC90 values are summarized in Table 2 and Table 3,
respectively. Our results show that all the ARVs tested have
inhibitory activity in SVG, PFA, MDM and PBMC, but with
variable potencies (Tables 2 and 3). Of note, the EC50 and EC90
values for 3TC, d4T and ZDV were consistently higher in the
SVG astrocytes and PFA compared to those in MDM and PBMC,
suggesting reduced HIV-1 inhibitory activity by these particular
NRTIs in astrocytes.
The NRTIs d4T and ZDV have markedly reduced
effectiveness in astrocytes compared to macrophages
and PBMC
To better understand the apparent disparity between the
inhibitory activities of 3TC, d4T and ZDV in astrocytes compared
to the other cell models, we next undertook statistical analyses of
the EC50 and EC90 values for these NRTIs in astrocytes compared
to MDM and PBMC (Table 4). Here, we focussed on the results
with PFA rather than SVG cells, as PFA represent the more
relevant of the two cellular models for astrocytes in vivo. These
Figure 1. HIV-1 inhibitory activity of ARVs in primary cells. Virus
inhibition assays were performed in PFA (A), MDM (B) and PBMC (C)
using titrating amounts of ARVs, as described in Materials and Methods.
The inhibition curves were generated as described in Materials and
Methods, and were used to calculate the EC50 and EC90 values that are
shown in Table 2 and Table 3, respectively. The data are a compilation
of 4 independent experiments, each using cells obtained from separate
independent donors, with each experiment conducted in triplicate.
Shown are the means and SEM of these data.
doi:10.1371/journal.pone.0062196.g001
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analyses showed that the EC50 values for 3TC, d4T and ZDV in
astrocytes were 8.8-, 142- and 262-fold greater than that in MDM,
respectively (p,0.01). The EC50 values for d4T and ZDV in
astrocytes were 33- and 164-fold greater than that in PBMC
(p,0.01), respectively, but there was no difference for 3TC. The
EC90 values for 3TC, d4T and ZDV in astrocytes were 63-, 382-
and 202-fold greater than that in MDM, respectively (p,0.01).
The EC90 values for d4T and ZDV in astrocytes were 18- and 92-
fold greater than that in PBMC (p,0.01), respectively. The EC90
for 3TC in astrocytes was a modest 4.3-fold greater than that in
PBMC, which neared significance. These results indicate that the
NRTIs d4T and ZDV, and to a lesser extent 3TC, have reduced
potency against HIV-1 in astrocytes compared to macrophages
and PBMC in vitro.
3TC, d4T and ZDV EC90 values in astrocytes exceed those
achieved in the CSF
For an ARV to have effective inhibitory activity in vivo, its in vitro
EC90 needs to fall below (or be equivalent to) the drug
concentration that is achieved in the relevant tissue compartment
[20,21]. Therefore, although the preceding analyses showed that
d4T and ZDV (and to a lesser degree 3TC) have reduced in vitro
HIV-1 inhibitory activity in astrocytes compared to macrophages,
the central issue that may have relevance to Neuro-cART
regimens is whether their elevated EC90 values in astrocytes
places these concentrations above what can be achieved by the
drug in the CSF. We therefore next compared the EC90 values of
each ARV obtained in the different cell models to the respective
concentration range achievable in the CSF (for astrocytes and
MDM) or plasma (for PBMC) (Figure 2). For these comparisons,
the shaded boxes in Figure 2 indicate the physiological drug
concentration ranges for each ARV in the CSF (Fig. 2A, B) and
plasma (Fig. 2C), and the orange triangles represent the EC90
values of each ARV in astrocytes (Fig. 2A), macrophages (Fig. 2B)
and PBMC (Fig. 2C). Here, the boxes shaded green indicate where
the ARV EC90 falls below the physiological drug concentration
range, the boxes shaded orange indicate where the ARV EC90 falls
within the physiological drug concentration range, and the boxes
shaded in red indicate where the ARV EC90 exceeds the
physiological concentration range. These analyses show that the
NRTIs 3TC, d4T and ZDV have EC90 values in astrocytes that
exceed the achievable CSF drug concentrations (Fig. 2A). In
contrast, the NRTI ABC, the NNRTIs EFV, ETR and NVP, and
the integrase inhibitor RAL have EC90 values in astrocytes that are
below or within the physiological concentration ranges in the CNS
(Fig. 2A), and all the ARVs have EC90 values in macrophages
(Fig. 2B) and PBMC (Fig. 2C) that are below or within the
Table 2. ARV EC50 values for inhibition of HIV-1 in different
cell types.
EC50 (mM) +/2 SEa (mM)
ARV SVG PFA PBMC MDM
Abacavir 0.05660.011 0.00460.001 0.11760.028 0.01060.003
Lamivudine 1.44860.204 0.31760.055 0.31560.107 0.03660.059
Stavudine 0.57860.189 5.96360.622 0.17960.061 0.04260.046
Zidovudine 0.01760.003 1.31160.130 0.00860.002 0.00560.002
Efavirenz 0.00260.000 0.00260.000 0.00160.000 0.00160.000
Etravirine 0.00160.000 0.00160.000 0.00160.000 0.00160.000
Nevirapine 0.04560.006 0.11460.020 0.18260.068 0.16660.253
Raltegravir 0.00460.001 0.00760.001 0.00360.001 0.01660.010
aMean 50% effective concentration6the standard error from n = 4 independent
assays.
SVG, fetal astrocyte cell line; PFA, primary fetal astrocytes; PBMC, peripheral
blood mononuclear cells; MDM, monocyte-derived macrophages.
doi:10.1371/journal.pone.0062196.t002
Table 3. ARV EC90 values for inhibition of HIV-1 in different
cell types.
EC90 (mM) +/2 SEa (mM)
ARV SVG PFA PBMC MDM
Abacavir 0.36960.055 1.73860.354 1.31860.141 0.63660.084
Lamivudine 43.94264.805 13.45162.315 3.10160.471 0.21460.156
Stavudine 5.77561.466 74.96567.821 4.26160.645 0.19660.096
Zidovudine 0.20560.031 44.15764.384 0.48160.061 0.21960.041
Efavirenz 0.01060.002 0.00960.002 0.01260.002 0.00460.001
Etravirine 0.00360.001 0.00360.000 0.01060.001 0.00760.001
Nevirapine 0.54360.054 0.66960.114 0.86760.145 0.50860.345
Raltegravir 1.07260.162 0.09160.016 0.02460.003 0.09660.027
aMean 90% effective concentration6the standard error from n = 4 independent
assays.
SVG, fetal astrocyte cell line; PFA, primary fetal astrocytes; PBMC, peripheral
blood mononuclear cells; MDM, monocyte-derived macrophages.
doi:10.1371/journal.pone.0062196.t003
Table 4. HIV-1 inhibitory activity of ARVs in PFA compared to MDM and PBMCs.
ARV PFA compared to MDM PFA compared to PBMC
EC50 EC90 EC50 EC90
D p D p D p D p
Lamivudine 8.8 0.0079 63 0.0079 1.0 0.4524 4.3 0.0556
Stavudine 142 0.0079 382 0.0079 33 0.0079 18 0.0079
Zidovudine 262 0.0070 202 0.0048 164 0.0048 92 0.0095
D, fold change in EC50 or EC90 values.
P values (p) were determined using a non-parametric Mann Whitney U-test. Values ,0.05 were considered statistically significant.
PFA, primary fetal astrocytes; PBMC, peripheral blood mononuclear cells; MDM, monocyte-derived macrophages.
doi:10.1371/journal.pone.0062196.t004
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physiological concentration ranges in the CSF and plasma,
respectively. These results suggest that there may be insufficient
levels of 3TC, d4T and ZDV to inhibit HIV-1 infection of
astrocytes in vivo, but that these drugs are likely to retain sufficient
antiviral activity in the macrophage-lineage cellular compartments
of the CNS.
Discussion
Our results suggest that certain CNS penetrating ARVs used in
Neuro-cART regimens may not be effective against HIV-1
infection of astrocytes. 3TC, ZDV and d4T are used in Neuro-
cART regimens [8,22], but here we show that the concentration of
these drugs required to achieve virological suppression in
astrocytes is 12-, 110, and 187-fold higher than what is achievable
in the CSF, respectively. In contrast, 3TC, ZDV and d4T
achieved virus inhibition in PBMC and MDM at concentrations
that were below or within the respective concentration ranges that
are achieved in vivo. Our results suggest that these NRTIs may not
target all the susceptible HIV-1 target cell populations in the CNS,
with potential implications for their inclusion in Neuro-cART
regimens.
We observed some discordance in EC50 and EC90 values
between the astrocyte cell line and primary fetal astrocytes. This
highlights some of the limitations of using SVG for astrocyte work
and reinforces the need to use the ‘gold standard’ PFA for
confirmatory studies. In addition, while the EC50/EC90 values
generated here are useful and insightful, they were generated in
the context of a single round of infection. Therefore, further
studies are required to analyze ARV effectiveness in the context of
multiple rounds of infection.
Our recent studies showed that up to approximately 20% of
astrocytes can be infected with HIV-1 in vivo, and therefore
astrocytes represent a potentially significant reservoir of HIV-1 in
the CNS [6]. Astrocytes are critical for maintaining normal brain
homeostasis [23],_ENREF_17 and astrocyte dysfunction is known
to contribute to HIV-1 neuropathogenesis [1,4]. Continuing to use
Neuro-cART regimens containing 3TC, d4T or ZDV could
potentially lead to astrocyte infection remaining untargeted, which
may contribute to neurocognitive impairment despite virological
suppression in plasma. In support of this possibility, the prevalence
of HAND is increasing despite suppressive cART [24–27].
The current focus on HIV-1 cure and eradication strategies has
identified persistently infected viral reservoirs as a major barrier to
the successful elimination of the virus [28–30]. These viral
reservoirs are located within the brain, gut-associated lymphoid
tissue, bone marrow, and genital tract [31]. HIV-1 infection of
astrocytes is predominantly restricted to the expression of genes
encoding the regulatory/accessory HIV-1 proteins [32], some of
which are neurotoxic (for example the HIV-1 Tat protein) [33],
and contributes to the persistent viral reservoir within the brain
that is not cleared by the immune system or ARVs [29].
Confirming that the ARVs used in Neuro-cART regimens are
active against-, and are present at concentrations sufficient for
virological suppression in astrocytes may be important for
controlling this potentially significant viral reservoir, and may be
necessary to prevent the transcription of HIV-1 genes encoding
neurotoxic viral proteins. The optimal targeting of HIV-1 infected
astrocytes by ARVs may prevent the expansion of this HIV-1
infected cellular reservoir and potentially aid virus eradication
efforts, and may also potentially contribute to better treatment
outcomes by reducing neurotoxicity.
While we have shown that both ZDV and d4T have markedly
reduced effectiveness in astrocytes compared to macrophages, the
underlying mechanism for this remains unknown. All the NRTIs
tested here require activation from their inactive native form by
three sequential phosphorylation events. In the case of ZDV and
d4T, the un-phosphorylated form is converted to the mono-, di-
and tri-phosphorylated forms by the cellular thymidine kinases,
thymidylate kinase and deoxynucleoside diphosphate kinase,
respectively [34]. In contrast, 3TC (whose reduced HIV-1
Figure 2. Comparison of ARV EC90 values in astrocytes,
macrophages and PBMC to achievable in vivo concentrations.
The ARV EC90 values determined in PFA, MDM and PBMC were
compared to the relevant in vivo drug concentrations. PFA (A) and MDM
(B) EC90 values were compared to the in vivo CSF drug concentration
range, and PBMC EC90 values (C) were compared to the in vivo plasma
drug concentration range. EC90 values are shown as red triangles with
error bars representing the SE. Shaded boxes denote the relevant in
vivo drug concentration range in either CSF (A and B) or plasma (C). The
boxes shaded green indicate where the ARV EC90 falls below the
physiological drug concentration range, the boxes shaded orange
indicate where the ARV EC90 falls within the physiological drug
concentration range, and the boxes shaded in red indicate where the
ARV EC90 exceeds the physiological concentration range.
doi:10.1371/journal.pone.0062196.g002
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inhibitory activity in astrocytes is relatively modest compared to
that of d4T and ZDV) and ABC only have the final phosphor-
ylation event in common, indicating unique cellular kinases are
involved in their initial phosphorylation events. The drug is only
active against the HIV-1 reverse transcriptase once the drug is tri-
phosphorylated, by competing with the natural dNTP substrate for
incorporation into DNA and causing chain termination. Three
possible explanations could address the reduced effectiveness of
d4T and ZDV in astrocytes; differences in cellular uptake of
NRTIs, inefficient or incomplete drug activation (due to lower
levels of cellular kinases or competition with the natural substrates
for the kinases), and inefficient incorporation into DNA (due to
higher levels of endogenous nucleotides). To this end, Perno et al.
demonstrated that ZDV was more potent against HIV-1 infection
in macrophage lineage cells due to lower levels of competing
endogenous thymidine [35], which is a finding that is supported by
our experiments when comparing EC90 values of ZDV between
PBMC and MDM. Future work will explore this area to better
understand the underlying cause of the markedly reduced
effectiveness of the d4T and ZDV NRTI thymidine analogues in
astrocytes.
In conclusion, the results of our study show that certain NRTIs,
in particular the thymidine analogues ZDV and d4T (and to a
lesser degree 3TC) have reduced HIV-1 inhibitory astrocytes in
vitro compared to macrophage-lineage cells, and furthermore that
the inhibitory concentrations of 3TC, ZDV and d4T in astrocytes
exceed those achievable in the CSF. Thus, Neuro-cART regimens
containing ZDV, d4T and/or 3TC may not effectively target
HIV-1 infected astrocytes of the CNS. Furthermore, our results
are the first to show differential ARV efficacy in brain cells,
thereby introducing an important principle in the future analysis of
ARVs.
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